GLP-1 receptor agonists are a class of peptide-based compounds originally studied for metabolic conditions. They work partly by slowing the rate at which the stomach empties and by reducing appetite signals in the brain. Over recent years they have become widely used by people pursuing significant weight loss, including many who later consider aesthetic or body contouring surgery.
A narrative review published in a peer-reviewed aesthetic surgery journal took a close look at what the emerging evidence says about this overlap. The authors pulled together perioperative safety data, body composition studies, and existing aesthetic surgery literature to ask a straightforward question: does using a GLP-1 receptor agonist before surgery change how that surgery should be planned and performed?
The short answer from the review is yes, in several ways that surgeons and their patients may not have fully considered yet.
How GLP-1 receptor agonists work in brief
GLP-1 stands for glucagon-like peptide-1, a hormone the gut produces naturally after eating. Synthetic peptides that activate the GLP-1 receptor mimic and extend this signal. The result is a slower rate of gastric emptying, meaning food and liquid sit in the stomach longer than usual, combined with a reduced drive to eat.
These effects are well documented and are precisely why the compounds produce meaningful weight loss. However, the same mechanisms that slow gastric emptying in everyday life do not simply switch off when a person follows standard pre-surgical fasting instructions. The review notes that perioperative data from mixed surgical populations suggest some GLP-1 receptor agonist users may still have retained gastric contents even after following conventional fasting protocols. That is a clinically relevant observation for anesthesiology teams assessing aspiration risk.
Wound complication signal in the literature
One of the more concrete findings the review surfaces involves wound healing. Emerging evidence in aesthetic and body contouring patient groups points to higher rates of wound complications in people using GLP-1 receptor agonists compared with matched controls.
The review specifically cites data showing wound dehiscence, a complication where a surgical incision separates before it has fully healed, occurring in approximately 5.19 percent of users of one GLP-1 receptor agonist versus about 2.78 percent in matched controls. That roughly doubles the observed rate, which the authors consider a meaningful signal even while acknowledging that prospective, aesthetics-specific data remain limited.
The review does not establish a definitive mechanism for this difference, but the authors suggest that rapid weight loss, nutritional shifts, and potential effects on tissue quality may all play a role. They frame this as a finding that warrants individualized risk assessment rather than a blanket contraindication.
Lean mass reduction and tissue quality
Significant weight loss of any kind tends to reduce both fat mass and lean mass. The review highlights that GLP-1 receptor agonist associated weight loss may coincide with clinically relevant reductions in lean tissue, meaning muscle and supportive connective structures, not just fat.
For aesthetic surgeons, this matters because the quality and quantity of soft tissue directly influences what can be achieved with contouring procedures and how well surgical results hold over time. People who have lost a large amount of weight rapidly may present with what the review describes as sarcopenic morphologies, a pattern where the underlying muscle framework is reduced relative to what might be expected from the person's size or surgical history.
The authors draw a comparison to principles already established in massive weight loss body contouring, a subspecialty that has long grappled with patients who arrive after bariatric surgery with loose skin, reduced subcutaneous fat, and compromised tissue integrity. The review argues that GLP-1 receptor agonist users may require a similar adapted framework even if their total weight loss is smaller.
Perioperative planning implications
The review's practical recommendations center on a shift toward more individualized, multidisciplinary planning. Rather than treating GLP-1 receptor agonist use as a simple checkbox on a pre-operative form, the authors encourage surgeons to coordinate with anesthesiology teams and follow institutional policies around fasting and aspiration risk.
Symptom screening is highlighted as important. Patients who report ongoing nausea, bloating, or other signs of delayed gastric emptying may warrant additional precautions or modified anesthetic approaches. The review does not prescribe a single protocol but emphasizes that a one-size-fits-all approach to fasting in this population is likely insufficient.
Timing of surgery relative to GLP-1 receptor agonist use is also discussed as a consideration. The review notes that adapting when surgery occurs in relation to a patient's dosing schedule may be one lever available to surgeons and their teams, though it acknowledges that the optimal approach is not yet established by prospective data.
Limitations of the current evidence base
The review is candid about what the literature does not yet support. Prospective data focused specifically on aesthetic surgery patients using GLP-1 receptor agonists are limited. Much of the perioperative safety evidence comes from mixed surgical populations, meaning patients undergoing a wide range of procedures, which may not map directly onto elective aesthetic procedures.
The wound complication data, while noteworthy, comes from early cohort observations rather than randomized controlled trials. The authors present the review as a conceptual framework and a call for more rigorous, aesthetics-specific research rather than as definitive clinical guidance.
Early data points at a genuine need for this research. As GLP-1 receptor agonist use continues to expand among people who are also candidates for aesthetic surgery, the gap between clinical practice and evidence-based guidance is likely to grow without dedicated study.
What this means for researchers and the field
The narrative review represents an effort to synthesize a rapidly moving area before the prospective trial data catch up. The authors frame their contribution as a practical conceptual framework for surgeons, drawing on classical massive weight loss body contouring principles and applying them to a newer patient phenotype.
For researchers interested in GLP-1 receptor agonist pharmacology, the review is a useful reminder that the downstream effects of these peptides extend well beyond metabolic outcomes. Gastric motility, tissue composition, wound biology, and surgical risk all appear to be touched by the same mechanisms that produce the compounds' better-known effects on appetite and weight.
The literature suggests this is a field where interdisciplinary collaboration between metabolic medicine, anesthesiology, and surgery will be essential as the evidence base develops. The review's authors encourage prospective studies designed specifically around aesthetic surgery populations to fill the gaps that currently require clinical judgment to bridge.
